Arrhythmias & electrophysiologyTrial design
Left atrial appendage closure in patients with non-valvular atrial fibrillation and end stage chronic KIDNEY disease: Rationale and design of the prospective randomized LAA-KIDNEY trial
- prospective, multicenter, randomized controlled clinical trial
- rationale and design
- 1:1 randomization
- ∼35 centers in Germany, Belgium and the Czech Republic
- intention-to-treat analysis
Study context
- Population
- Patients with non-valvular atrial fibrillation (AF) and kidney failure at high risk of both, ischemic stroke and bleedingplanned number to be randomized
- Participants
- 272 patients
- Planned comparison
- percutaneous left atrial appendage (LAA) closure with best medical care
- Primary endpoint
- Net clinical benefit: time to a composite of first stroke (including ischemic or hemorrhagic strokes), systemic embolism, cardiovascular or unexplained death or major bleeding (BARC 3-5)
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Left atrial appendage closure in patients with non-valvular atrial fibrillation and end stage chronic KIDNEY disease: Rationale and design of the prospective randomized LAA-KIDNEY trial. Am Heart J. Published 8 May 2026. doi:10.1016/j.ahj.2026.107474
Summarised from the published abstract; every number is checked against it